C/EBPβ Is a MYB- and p300-Cooperating Pro-leukemogenic Factor and Promising Drug Target in Acute Myeloid Leukemia

Scientists characterized a group of natural sesquiterpene lactones, previously shown to suppress MYB activity, for their potential to decrease AML cell proliferation.
[Oncogene]
Yusenko, M. V., Trentmann, A., Casolari, D. A., Abdel Ghani, L., Lenz, M., Horn, M., Dörner, W., Klempnauer, S., Mootz, H. D., Arteaga, M. F., Mikesch, J.-H., Andrea, R. J. D., Gonda, T. J., Müller-Tidow, C., Schmidt, T. J., & Klempnauer, K.-H. (2021). C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia. Oncogene, 1–13. https://doi.org/10.1038/s41388-021-01800-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

YTHDF2 Is a Potential Target of AML1/ETO-HIF1α Loop-Mediated Cell Proliferation in t(8; 21) AML

Scientists showed that YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) was highly expressed in t(8;21) acute myeloid leukemia (AML) patients and associated with a higher risk of relapse and inferior relapse-free survival. Knockdown of YTHDF2 in leukemia cells caused an impaired cell proliferation rate in vitro and in mice.
[Oncogene]
Abstract
Bookmark

No account yet? Register

0
Share

Allogeneic Hematopoietic Cell Transplantation with Cord Blood versus Mismatched Unrelated Donor with Post-transplant Cyclophosphamide in Acute Myeloid Leukemia

Scientists compared the allogeneic hematopoietic cell transplantation (allo-HCT) outcomes of cord blood transplantation versus single-allele-mismatched mismatched unrelated donor allo-HCT with post-transplant cyclophosphamide in acute myeloid leukemia.
[Journal of Hematology & Oncology]
Dholaria, B., Labopin, M., Sanz, J., Ruggeri, A., Cornelissen, J., Labussière-Wallet, H., Blaise, D., Forcade, E., Chevallier, P., Grassi, A., Zubarovskaya, L., Kuball, J., Ceballos, P., Ciceri, F., Baron, F., Savani, B. N., Nagler, A., & Mohty, M. (2021). Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. Journal of Hematology & Oncology, 14(1), 76. https://doi.org/10.1186/s13045-021-01086-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

T-Cell-Based Immunotherapy of Acute Myeloid Leukemia: Current Concepts and Future Developments

The stellar successes of immunotherapies that harness the power of T cells to treat solid tumors and an improved understanding of the immune systems of patients with hematologic malignancies have led to major efforts to develop immunotherapies for the treatment of patients with AML.
[Leukemia]
Daver, N., Alotaibi, A. S., Bücklein, V., & Subklewe, M. (2021). T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia, 1–21. https://doi.org/10.1038/s41375-021-01253-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers

Hoth Therapeutics, Inc. announced it intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple orphan diseases, which are rare diseases that affect less than 200,000 people in the US. HT-KIT targets a shared cell signaling pathway that may have therapeutic potential for multiple rare cancers.
[Hoth Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia

Recipients of less-intensive therapies were older, had more comorbidities, more adverse cytogenetics, and worse Karnofsky performance status.
[Blood]
Sorror, M. L., Storer, B. E., Fathi, A. T., Brunner, A. M., Gerds, A. T., Sekeres, M. A., Mukherjee, S., Medeiros, B. C., Wang, E. S., Vachhani, P., Shami, P. J., Peña, E., Elsaway, M., Adekola, K. U. A., Luger, S., Baer, M. R., Rizzieri, D., Wildes, T., Koprivnikar, J., … Estey, E. H. (2021). Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. Blood, blood.2020008812. https://doi.org/10.1182/blood.2020008812 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Identification of Therapeutic Targets of the Hijacked Super-Enhancer Complex in EVI1-Rearranged Leukemia

The authors unraveled key components of G2DHE-bound transcription factors involved in the deregulation of EVI1.
[Leukemia]
Kiehlmeier, S., Rafiee, M.-R., Bakr, A., Mika, J., Kruse, S., Müller, J., Schweiggert, S., Herrmann, C., Sigismondo, G., Schmezer, P., Krijgsveld, J., & Gröschel, S. (2021). Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1 -rearranged leukemia. Leukemia, 1–12. https://doi.org/10.1038/s41375-021-01235-z Cite
Full Article
Bookmark

No account yet? Register

0
Share

iPSC Modeling of Stage-Specific Leukemogenesis Reveals BAALC as a Key Oncogene in Severe Congenital Neutropenia

Researchers established a model of stepwise leukemogenesis in congenital neutropenia (CN)/acute myeloid leukemiausing CRISPR-Cas9 gene editing of CN patient-derived iPSCs.
[Cell Stem Cell]
Dannenmann, B., Klimiankou, M., Oswald, B., Solovyeva, A., Mardan, J., Nasri, M., Ritter, M., Zahabi, A., Arreba-Tutusaus, P., Mir, P., Stein, F., Kandabarau, S., Lachmann, N., Moritz, T., Morishima, T., Konantz, M., Lengerke, C., Ripperger, T., Steinemann, D., … Skokowa, J. (2021). iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropenia. Cell Stem Cell, 0(0). https://doi.org/10.1016/j.stem.2021.03.023 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Musculoskeletal Impairments in Children Receiving Intensive Therapy for Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplant: A Report from the Children’s Oncology Group

Children with acute myeloid leukemia, relapsed acute lymphoblastic leukemia, or undergoing hematopoietic stem cell transplant were systematically assessed for musculoskeletal impairments as part of Children’s Oncology Group study ACCL0934.
[Pediatric Blood & Cancer]
Thompson, J., Fisher, B., Sung, L., Dvorak, C., Dang, H., Lo, T., & Alexander, S. (n.d.). Musculoskeletal impairments in children receiving intensive therapy for acute leukemia or undergoing hematopoietic stem cell transplant: A report from the Children’s Oncology Group. Pediatric Blood & Cancer, n/a(n/a), e29053. https://doi.org/https://doi.org/10.1002/pbc.29053 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission

Bristol Myers Squibb announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Onureg® as a maintenance therapy in adult patients with acute myeloid leukemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation.
[Bristol Myers Squibb]
Press Release
Bookmark

No account yet? Register

0
Share

Isoform-Specific and Signaling-Dependent Propagation of Acute Myeloid Leukemia by Wilms Tumor 1

Scientists showed that the transcription factor Whilms tumor 1 formed a major node in the rewired mutation-specific gene regulatory networks of multiple acute myeloid leukemia (AML) subtypes.
[Cell Reports]
Potluri, S., Assi, S. A., Chin, P. S., Coleman, D. J. L., Pickin, A., Moriya, S., Seki, N., Heidenreich, O., Cockerill, P. N., & Bonifer, C. (2021). Isoform-specific and signaling-dependent propagation of acute myeloid leukemia by Wilms tumor 1. Cell Reports, 35(3). https://doi.org/10.1016/j.celrep.2021.109010 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share